We have acquired the new spectralis OCT. This will be operational hopefully mid June. The spectralis OCT is THE market leader in OCT boasting the highest resolution of all the currently available OCT’s.
This will greatly enhance our ability to detect and follow glaucoma.
It will also of course enable us to detect retinal pathology such as macular degeneration, cystoid macular oedema, macular holes and other pathologies.